



vh2021

12th Australasian Viral Hepatitis Conference

**30 May 2021:
Sofitel Central, Brisbane**

**31 May - 1 June 2021:
Sydney Masonic Centre, Sydney**

Conference Handbook

@ashmmedia #VH2021

THANK YOU TO OUR SPONSORS & SUPPORTERS



GILEAD

Platinum Sponsor

abbvie

Silver Sponsor



Australian Government
Department of Health

Major Supporter

CONTENTS

Conference Co-Convenors	02
Program Committee	03
Theme Committees	04
Invited Speakers	05
Wifi & Conference App	12
Floor Plans	14
Exhibition Directory	16
Live Program.....	20
On Demand Program.....	29
On Demand Poster Listing	32

Published in 2021

by the Australasian Society
for HIV, Viral Hepatitis and
Sexual Health Medicine

NATIONAL OFFICE:

Level 3, 160 Clarence Street,
Sydney, NSW, Australia

M 0458 291 166

E conference@ashm.org.au

W www.ashm.org.au

ABN: 48 264 545 457

CFN: 17788

© ASHM 2021 Design and

layout by Shelly Lavender

Printed by TTR Print Management

CONFERENCE ENVIRONMENT POLICY

ASHM Conference and Events Division implements a waste-reduction policy that addresses:

- Reduce, Reuse, Recycle. This is done before, during and after each conference.
- ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
- ASHM Conference & Events Division will endeavor to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.
- ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

CONFERENCE CO-CONVENORS



Jason Grebely

Jason Grebely is a Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Sydney. Jason's training and research is based in the field of epidemiology, with a specific focus on clinical epidemiology. Jason has a BSc in Biochemistry and Molecular Biology and a PhD in Pharmacology and Therapeutics, both from the University of British Columbia in Vancouver, Canada. He completed a Postdoctoral Fellowship in Clinical Epidemiology at the University of New South Wales in Sydney, Australia. Jason is also the President of the International Network on Hepatitis in Substance Users.



Kevin Marriott

Kevin is the Director of Programs at Hepatitis Australia and has worked in the area of blood borne viruses and sexual health for 25 years. Kevin's background is in Human and Community Services including direct service provision, health promotion, program management and executive leadership positions.



Mark Stoové

Mark Stoové is Head of Public Health at the Burnet Institute and has researched the transmission and impact of blood borne viruses among key risk populations for almost 20 years. A primary focus of his work is understanding the epidemiological, behavioural and biological drivers of infections and the translation of research evidence into effective public health policy and practice.



Scott Bowden

Scott Bowden is a Senior Scientist at VIDRL and an adjunct Professor in Microbiology at Monash University. He has served on Government committees helping develop strategies and testing policies for viral hepatitis. He has published over 180 papers and is an expert on the diagnosis of the hepatitis viruses.

PROGRAM COMMITTEE

Behzad Hajarizadeh

The Kirby Institute, UNSW Sydney

Gabrielle Bennett

St Vincent's Melbourne

Ian Anderson

University of Queensland

Joanne Bryant

Centre for Social Research
in Health, Faculty of Arts and
Social Sciences at UNSW

Joseph Doyle

Monash University

Jennifer MacLachlan

WHO Collaborating Centre for
Viral Hepatitis at The Doherty
Institute

Kelly Hayes

Menzies School of Health Research

Kristen Mckee

Storr Liver Centre,
Westmead hospital

Lauren Bradley

Australian Injecting & Illicit Drug
Users League (AIVL)

Margaret Littlejohn

Victorian Infectious Diseases
Reference Laboratory - VIDRL

Melinda Hassall

Australasian Society for HIV,
Viral Hepatitis and Sexual Health
Medicine (ASHM)

Olivia Dawson

Australasian Society for HIV,
Viral Hepatitis and Sexual Health
Medicine (ASHM)

Sami Stewart

Australasian Society for HIV,
Viral Hepatitis and Sexual Health
Medicine (ASHM)

Sam White

Hepatitis Queensland

Shelly Kerr

Australasian Society for HIV,
Viral Hepatitis and Sexual Health
Medicine (ASHM)

Troy Combo

Burnet Institute /
University of Queensland,
School of Public Health

THEME COMMITTEES



Biomedical Science & Clinical Care

Jacqui Richmond

Burnet Institute

Phillip Read

Kirketon Road Centre



Community & Social Research

Jake Rance

Centre for Social Research in Health, UNSW

Nikki Parry

QuIHN



Epidemiology, Public Health & Prevention

Behzad Hajarizadeh

The Kirby Institute, UNSW Sydney

Jennifer MacLachlan

WHO Collaborating Centre for Viral Hepatitis
at The Doherty Institute

KEYNOTE SPEAKERS

INTERNATIONAL



Natasha Martin

Associate Professor in the Division of Infectious Diseases and Global Public Health in the Department of Medicine at the University of California San Diego

Natasha is an Associate Professor in the Division of Infectious Diseases and Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease modeler whose work evaluates the impact and cost-effectiveness of viral hepatitis and HIV prevention interventions among high risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading modelers examining the potential impact of HCV treatment as prevention, and what prevention scale-up is required for HCV elimination. In 2016, she was selected by The Economist magazine as a “HCV Change Maker”, providing “fresh thinking on the road to elimination of HCV.”

KEYNOTE SPEAKERS

INTERNATIONAL



Saeed Sadiq Hamid

Professor, Department of Medicine and Director of the Clinical Trials Unit, The Aga Khan University, Karachi, Pakistan

Dr Saeed Sadiq Hamid is Professor, Department of Medicine and Director of the Clinical Trials Unit at The Aga Khan University, Karachi, Pakistan. He formerly served as Chair, Department of Medicine from 2008-2018. He trained in Medicine and Gastroenterology in the UK, and in Hepatology at University of Texas Southwestern Medical School, Dallas, USA. He has been Vice President, Pakistan Society of Gastroenterology and President of the Pakistan Society for the Study of Liver Diseases (PSSLD). He is currently Chair of Hepatology Interest Group of the World Gastroenterology Organization, has been a member of the Executive Council of the Asian Pacific Association for the Study of the Liver (APASL) from 2006-2010 and has chaired the WHO Guidelines Development Group for Hepatitis C in 2015 and again in 2017. He sits on Advisory Committees of the Coalition for Global Hepatitis Elimination (CGHE) and the Hepatitis Fund. His main research interests are viral hepatitis and Liver Failure. He has been an author on over 160 peer reviewed publications and three book chapters. He has mentored a number of postgraduate GI trainees, PhD and other graduate students.



Yusuke Shimakawa

MD, DTM, MSc, PhD, Senior epidemiologist, Emerging Disease Epidemiology Unit, Institut Pasteur, Paris, France

Dr. Yusuke Shimakawa is a senior epidemiologist at the Institut Pasteur, Paris, an expert on viral hepatitis control in Africa. He obtained a medical degree from the Jikei University, Tokyo, Japan, and MSc and Ph.D. in epidemiology from the London School of Hygiene and Tropical Medicine (LSHTM). He has professional experience in working in resource-limited countries as a clinician (MSF in Thailand) or an epidemiologist (MRC Unit The Gambia). He leads several research projects in Africa including the NéoVac (neonatal vaccination against hepatitis B) and HBV LAMP (simplified management of chronic hepatitis B virus infection). He has been commissioned by the WHO for external reviews and conduct of systematic reviews to inform the guidelines for the prevention of mother-to-child transmission of hepatitis B.

KEYNOTE SPEAKERS

LOCAL



Chris Gough

Chris Gough, Executive Director of the Canberra Alliance for Harm Minimisation and Advocacy (CAHMA) and The Connection health service

Mr Chris Gough is Executive Director of the Canberra Alliance for Harm Minimisation and Advocacy (CAHMA) and The Connection health service. He holds a Bachelor of Science and Bachelor of Honours in entomology and developmental parasitology from the University of Queensland. He has over ten years of experience in the blood borne virus and alcohol, tobacco and other drug sectors, and has identified as a person who uses drugs for 20 years. Chris' expertise centres around peer and consumer driven programming including peer education, peer treatment support, community development, consumer representation and advocacy. He has worked at the Medically Supervised Injecting Centre (MSIC) and the NSW Users and AIDS Association (NUAA). Chris has served on the Boards of the Australian Federation of AIDS Organisations (AFAO), NUAA, the ACT Alcohol Tobacco and Other Drug Association (ATODA) and is currently the Secretary of the Australian Illicit and Injecting Drug Users League (AIVL).

KEYNOTE SPEAKERS

LOCAL



Dr Dawn Casey PSM FAHA

Deputy CEO NACCHO

Dawn Casey is a Tagalaka traditional owner from North Queensland. Dawn joined the National Aboriginal Community Controlled Health Organisation in 2016, is Deputy CEO and currently co-chairs the COVID-19 Indigenous Advisory Committee. Dawn has held part-time positions as Chair of ILC and IBA and full-time positions as Director of the Western Australian Museum, Powerhouse Museum and National Museum of Australia. Dawn was responsible for managing the design and construction of the National Museum of Australia and the Australian Institute of Aboriginal and Torres Strait Islander Studies through a world first project delivery alliance contract.

Dawn's career also includes a number of key executive positions in the Public Sector in areas including: Department of Prime Minister and Cabinet, Indigenous Affairs, Cultural Heritage and Overseas Aid and Development. Dawn has been awarded; three Honorary Doctorates (QLD Charles Sturt, QLD and Macquarie Universities), Commonwealth Government's Public Service Medal (PSM), Australian Government's Centenary Medal, three Australia Day Public Service Medals, the Australian Institute of Architects' Clem Cummings Award and a Fellow of the Australian Academy of the Humanities (FAHA).



Zhihong Gu

Zhihong Gu, Program Manager, HIV, Hepatitis and Sexual Health Program at the Ethnic Communities Council of Queensland

Zhihong Gu is the program manager for the HIV, Hepatitis and Sexual Health Program at Ethnic Communities Council of Queensland. She has been in this role for about 14 years working with a range of culturally and linguistically diverse communities in Queensland.

INVITED SPEAKERS

LIVE PROGRAM

Colette McGrath

Service Director Population Health, Justice Health Forensic Mental Health Network

Esha Leyden

Peer Worker, QuIHN

Jack Wallace

Senior Research Officer, Burnet Institute

Jane Davies

Co-director Infectious Diseases, Menzies

Jennifer MacLachlan

Senior Epidemiologist, WHO Collaborating Centre For Viral Hepatitis

Marianne Martinello

Senior Lecturer, The Kirby Institute, UNSW Sydney

Mary-Anne Rushford

Manager, Bolton Clarke Homeless Persons Program

Megan Hughes

Cnc - Tasmanian Eliminate Hepatitis C Australian Outreach Project, Sexual Health Services Tasmania

Nick Scott

Econometrician, Burnet Institute

Peter Revill

Senior Medical Scientist and Laboratory Head, Doherty Institute

Phill Read

Director, Sexual Health and Blood Borne Viruses - SESLHD/ Director, Kirketon Road Centre

Sinead Sheils

Hepatology Nurse Practitioner, Royal Prince Alfred Hospital

Stuart Manoj-Margison

Director - Blood Borne Viruses, Sexually Transmissible Infections, and Torres Strait Health Policy Section, Australian Government Department of Health

Susan Matthews

Deputy Director, International Centre for Point of Care Testing

Tim Broady

Research Fellow, Centre for Social Research In Health, UNSW



**CREATING A BETTER,
HEALTHIER WORLD**



***The way we see it, the impossible is not possible.
The impossible is simply what hasn't been achieved yet.***

In Australia and New Zealand we are determined to face this challenge every day. We are determined to create a better, healthier world and to prove impossible wrong.

What we do: Creating possible in ANZ





The quest for possible began when a group of determined scientists founded Gilead Sciences, intent on conquering the impossible challenge of HIV. We arrived in Australia in 1999 with a focus on ensuring access to our treatments for all Australians.

Today, Science, grit and determination remain Gilead's DNA. We are grounded by the desire to help patients in need, undaunted by what has been deemed impossible. We've used our decades of experience in HIV, to tackle other viruses such as hepatitis B and C and COVID-19 and remain dedicated to elimination of HCV and HIV in Australia.

Our future is creating possible. We are committed to tackling HIV, HBV, HCV and blood cancer, we now extend our focus into new diseases including solid tumour cancer, inflammatory and fibrotic diseases. We will embrace new frontiers in technology and medicine, form new partnerships and continue our focus on prevention, treatment and the possibility of cures.



Our priorities are dictated by the people in greatest medical need of options, including:

-  Delivering innovative treatments for Australians living with blood cancer
-  Providing a treatment option for patients hospitalized with COVID-19
-  Developing 11 treatments in 20 years to prevent and treat HIV, ultimately working towards a cure
-  Helping treat the 120,000 Australians still living with potentially curable Hepatitis C.¹

Gilead in Australia



1999 Gilead arrived in Australia 21 years ago

100 Employees

\$8 Million+ since 2015 Invested in grants and research to support local R&D. Gilead is currently one of the top 10 investors in clinical trials in Australia²

Giving Back at Gilead

Gilead works with organisations across all our therapeutic areas to help improve health access, eliminate the barriers to healthcare, advance education and support local communities. Some of our programs include:

THE GILEAD AUSTRALIA
FELLOWSHIP
RESEARCH GRANTS PROGRAM

The Gilead Fellowship Grants Program awarded \$2 million over 10 years to 60 Australian research projects



Over \$250,000 awarded to Australian community projects as part of Gilead's global COMMIT program towards Hepatitis C elimination



Since 2020, over \$450,000 donated to Australian HIV community groups as part of the Together Grant and Getting to Zero Grant.

References

1. Burnet Institute and Kirby Institute. Australia's progress towards hepatitis C elimination: annual report 2020. Melbourne: Burnet Institute; 2020.
2. Australian Government. Aus Trials Clinical Trials Report. Available at: <https://www.austrade.gov.au/ArticleDocuments/284/Clinical-Trials-Capability-Report.pdf.aspx>. Accessed March 2021.

Gilead and the Gilead Creating Possible Logo are registered trademarks of Gilead Sciences, Inc. or its related companies. Gilead Sciences Pty Ltd, Level 6, 417 St Kilda Rd, Melbourne VIC.

AU-UNB-0017. Date of preparation April 2021

WIFI & CONFERENCE APP

Wi-Fi Details Brisbane

Connect to: Sofitel
Conference Wireless
Password: VIRALHEP21


Wi-Fi Details Sydney

Connect to: VH2021
Password: VH2021

The Conference App supported by



and is available to download from the
Apple app store or Google Play.



CONFERENCE APP

The conference app is the best way to stay informed during the conference and free to download. Here's what you can do with the app:

- View the program by time or session, read the abstracts, make notes and let others know what you think about the session by sharing it on Twitter
- Send your questions in to be answered and discussed during sessions
- Search for speakers, read their bio and see what presentations they are giving
- View a list of all the sponsors and exhibitors and check which booths they are at
- Build your own agenda
- Send a direct message to that person you have been trying to pin down for a meeting

How do I get the app?

For most attendees, you are able to download and install your mobile app from your Android or Apple App Stores.

- Search for 'Events App by EventsAIR' in the Apple App Store or Google Play Store

How do I log into the app?

Once you have found the app in your App Store:


1. Install the App.
2. The first time you open the app, you will need to enter the event code: **VH2021**
3. To login, enter your primary email address and pin which you would have received in your app instructions email and final registration confirmation email.

You are all set!

If you have any questions visit the conference team located at the Registration desk!


VENUE FLOOR PLAN & EXHIBITION BOOTHS

BRISBANE



VENUE FLOOR PLAN & EXHIBITION BOOTHS

SYDNEY



EXHIBITION DIRECTORY

Staff at the pharmaceutical company trade displays are precluded by law, and by Medicines Australia code from giving information about specific products to non-healthcare professionals.

Booth 2: Brisbane

Booth 3: Sydney



Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Booth 3: Brisbane

Booth 2: Sydney



As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.

Booth 4: Brisbane

Booth 4: Sydney



The Commonwealth Department of Health develops and delivers policies and programs and advises the Australian Government on health, aged care and sport. The Department works with a wide range of stakeholders to deliver an affordable, quality health and aged care system and better health, ageing and sport outcomes for all Australians.

Booth 5: Brisbane



**AUSTRALASIAN
HEPATOLOGY
ASSOCIATION**

Booth 5: Sydney

The Australasian Hepatology Association (AHA) is the peak professional body supporting and educating hepatology nurses and allied health professionals across Australia and New Zealand. Our vision is to facilitate a voice for health professionals caring for people affected by liver diseases, provide support for professional development and research, and promote networking within our speciality field. The AHA supports health professionals working across viral hepatitis, chronic liver disease, liver transplantation, liver cancer, health policy, sexual health, mental health, drug and alcohol, infectious diseases, Indigenous health, culturally and linguistically diverse (CALD) health, prison health and nutrition services. The Australasian Hepatology Association remains at the forefront of healthcare and community education and is recognised worldwide as a leader in developing innovative resources.

Tabletop: Brisbane



Tabletop: Sydney

At Roche, innovating healthcare is at the core of our business strategy through leading pathology solutions and supporting patient management. Our expanding knowledge and understanding of disease mechanisms leads us to deliver significant benefits to patients and healthcare professionals. Roche's diagnostic instruments and reagents help doctors detect diseases, select appropriate treatments and monitor patients' responses to care.

Booth 1: Brisbane



**Medical Technologies
Australia**

Booth 1: Sydney

Medical Technologies Australia 2021 announces new Major Fibroscan upgrades with SmartExam now with XXL capability and CAP – Steatosis for more accurate assessment in HCV, HBV, NAFLD, ASH and NASH. Typical of Echosens constant development to improve results using the same 50 Hz frequency with faster processors and software with broader parameters.

**The 12th Australasian
Viral Hepatitis Conference
is proudly supported by**



Australian Government

Department of Health

ASSOCIATED EVENTS

Cepheid Sponsored Symposium

Overview: Ambitious global targets call for a reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by the year 2030. Simplifying HCV testing, diagnosis and linkage to care is crucial to meeting these elimination targets. The TGA approval in May 2020 of the first point-of-care hepatitis C test for use in Australia constitutes a significant movement forward in simplifying testing algorithms. Presented by Marian Bloomfield and Kristen McKee, this session will focus on the implementation of point-of-care fingerstick testing in different settings.

Date: Monday 31 May,
Sydney Masonic Centre

Time: 1:15pm – 1:55pm



Hepatitis B s100 Case Discussion

Overview: Open to HBV s100 Prescribers only.
To register please contact Jane Teiken:

E: Jane.tieken@ashm.org.au

M: 0411 536 307

Date: Sunday 30 May,
Sofitel Brisbane Central

Room: Plenary

Time: 1:15pm – 1:55pm.



ashm

LIVE PROGRAM

DAY 1: SUNDAY 30 MAY – BRISBANE

8.00am	Registration Opens
9.10am - 11.00am	Opening Ceremony & Invited Speaker Session 01 Room: Ballroom 1 & 2 Chairs: Kevin Marriott, Hepatitis Australia & Jane Davies, Menzies School of Health Research
9.10am - 9.15am	Welcome to Country Shannon Ruska
9.15am - 9.20am	Committee Welcome Kevin Marriott, Hepatitis Australia, QLD
9.20am - 9.25am	Community Welcome Thomas Tu, University Of Sydney and Westmead Institute for Medical Research, NSW
9.25am - 9.30am	Government Welcome Hon Yvette D'Ath, Minister for Health and Ambulance Services, QLD
9.30am - 9.50am	Using data linkage to better understand progress towards viral elimination targets Jennifer MacLachlan, The Doherty Institute, VIC
9.50am - 10.10am	Stigma and discrimination Tim Broady, Centre for Social Research in Health, UNSW, NSW
10.10am - 10.30am	Mental Health Megan Hughes, Sexual Health Services Tasmania, TAS
10.30am - 11.00am	Questions & Discussion
11.00am - 11.05am	Hepatitis Australia Statement Carrie Fowle, Hepatitis Australia, ACT
11.00am - 11.30am	Morning Tea
11.30am - 1.00pm	Plenary 01 Room: Ballroom 1 & 2 Chairs: Katelin Haynes, Hepatitis Queensland & Linda Selvey, The University of Queensland
11.30am - 12.00pm	Keynote Presentation 01: Taking stock of HBV elimination efforts: Where are we now and what are the challenges for the future? Yusuke Shimakawa, Institut Pasteur, France
12.00pm - 12.30pm	Keynote Presentation 02: Hepatitis B in the CALD Community Zihong Gu, Ethnic Communities Council of Queensland, QLD
12.30pm - 12.45pm	Outcomes of the CT2 Study: A 'One-Stop-Shop' for Community-Based, General Practitioner-Led Hepatitis C Point-of-Care Testing and Treatment in Yangon, Myanmar Bridget Draper, Burnet Institute, VIC
12.45pm - 1.00pm	Hepatitis C micro-elimination in mental health settings using a nurse led model of care Kristen McKee, Storr Liver Centre, Westmead Hospital, NSW
1.00pm - 2.00pm	Lunch
1:15pm - 1.55pm	Hepatitis B s100 Case Discussion Room: Ballroom 1 & 2 <i>Open to HBV s100 Prescribers only. To register please contact Jane Telken: Jane.tiiken@ashm.org.au, M: 0411 536 307</i>

2.00pm - 3.30pm	Proffered Paper Session 01 Room: Ballroom 1 & 2 Chairs: Amanda Kvassay, QuiHN & Melinda Hassall, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
2.00pm - 2.15pm	Uptake of Perinatal Immunoprophylaxis for Infants Born to Women with a Record of Hepatitis B in Victoria (2009 - 2017) Anna Deng, WHO Collaborating Centre For Viral Hepatitis, Doherty Institute, VIC
2.15pm - 2.30pm	How do Mothers with Chronic Hepatitis B Understand and Experience the Prevention of Mother to Child Transmission Interventions in Victoria? Nafisa Yussf, WHO Collaborating Centre For Viral Hepatitis, Doherty Institute, VIC
2.30pm - 2.45pm	Tasmanian eliminate hepatitis c Australian outreach project (TEHCAO) Megan Hughes, Sexual Health Services Tasmania, TAS
2.45pm - 3.00pm	Interrupted Progress: Decline in Viral Hepatitis Testing and Care During Covid-19 Jennifer MacLachlan, The Doherty Institute, VIC
3.00pm - 3.05pm	Analysing the Effects of HBV Splice Variants on Wildtype HBV Replication Laura McCoullough, Victorian Infectious Diseases Reference Laboratory, VIC
3.05pm - 3.10pm	An Updated Estimate of the Annual Number of New Hepatitis C Infections Among People Who Inject Drugs in Australia Anna Palmer, Burnet Institute, VIC
3.10pm - 3.15pm	Data Linkage for Surveillance of Newly Acquired Hepatitis C Infections in Queensland: Early Findings and Implications for Policy and Practice Damin Si, Queensland Department Of Health, QLD
3.15pm - 3.20pm	Just a GP, Just a Finger Prick, Just an Hour Joss O'loan, Kombi Clinic, QLD
3.20pm - 3.25pm	Beyond the C: Hepatitis C Elimination in Your Practice Olivia Dawson, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, NSW
3.25pm - 3.30pm	Palen Creek Prison Cures; HCV Elimination in a Weekend Joss O'loan & Mim O'Flynn, Kombi Clinic, QLD
3.30pm - 4.00pm	Afternoon Tea
4.00pm- 6.15pm	Invited Speaker Session 02 Room: Ballroom 1 & 2 Chairs: Bridget Draper, Burnet Institute & Kevin Marriott, Hepatitis Australia
4.00pm - 4.20pm	Addressing viral hepatitis in regional and remote settings Jane Davies, Menzies School of Health Research, NT
4.20pm - 4.40pm	Engaging CALD communities with testing, monitoring and care for hepatitis B and C Jack Wallace, Burnet Institute, VIC
4.40pm - 5.00pm	Homelessness Mary-Anne Rushford, Bolton Clarke Homeless Persons Program, VIC
5.00pm - 5.30pm	Questions & Discussion
5.30pm - 6.15pm	Fit for purpose? HCV notification in the post DAA world Chairs: Linda Selvey, The University of Queensland Panellists: Nik Alexander, Queensland Injectors Health Network (QuiHN), QLD, Greg Dore, The Kirby Institute, UNSW Sydney, Margaret Hellard, Burnet Institute, VIC, Stephen Lambert, The University of Queensland, QLD
6:15pm - 6.45pm	Networking Drinks

LIVE PROGRAM

DAY 2: MONDAY 31 MAY – SYDNEY

7.30am	Registration opens
8.30am - 10.15am	Invited Speaker Session 03 Room: Grand Lodge Chairs: Jason Grebely, The Kirby Institute, UNSW Sydney & Carrie Fowlie, Hepatitis Australia
8.30am - 8.35am	Welcome to Country Yvonne Weldon
8.35am - 8.40am	Committee Welcome Mark Stooove, Burnet Institute, VIC
8.40am - 8.45am	Community Welcome Pamela Wood, Hepatitis Australia, VIC
8.45am - 9.05am	Leveraging learnings from Australian point-of-care testing networks to inform scale-up of hepatitis C RNA testing Susan Matthews, International Centre for Point of Care Testing, SA
9.05am - 9.25am	Patient perspectives on testing methods Esha Leydon, QulHN, QLD
9.25am - 9.45am	Linkage to care and sustainability of models Marianne Martinello, The Kirby Institute, UNSW, NSW
9.45am - 10.15am	Questions & Discussion
10.15am - 10.45am	Connecting with Care
10.15am - 10.20am	Introduction Conor Ashleigh, Filmmaker & Digital Communications Specialist
10.20am - 10.27am	Film Launch
10.27am - 10.45am	Panel Discussion Moderator: Conor Ashleigh, Filmmaker & Digital Communications Specialist Panellists: Rhondda Lewis, Cairns Sexual Health Service, QLD, Darren Russell, Cairns Sexual Health Service, QLD, Kathy Clark, Cairns Hepatitis Action Team, QLD
10.45am - 11.15am	Morning Tea
11.15am - 1.00pm	Plenary 02 Room: Grand Lodge Chairs: Nicole Allard, VIDRL Doherty Institute & Nick Scott, Burnet Institute
11.15am - 11.45am	Keynote Presentation 03: Taking stock of HCV elimination efforts: Where are we now and what are the challenges for the future? Natasha Martin, University of California San Diego, USA
11.45am - 12.15pm	Keynote Presentation 04: Community perspective: how are we actually engaging people in treatment and management for viral hepatitis Chris Gough, Canberra Alliance for Harm Minimisation and Advocacy (CAHMA) and The Connection Health Service, Canberra, ACT
12.15pm - 12.30pm	Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the Stop-C Study Behzad Hajarizadeh, The Kirby Institute, UNSW Sydney, NSW
12.30pm - 12.45pm	The C-LINK trial: a prospective randomised controlled trial showing that care-navigation post release from prisons increases linkage to hepatitis C care Alex Thompson, St Vincent's Hospital Melbourne, VIC
12.45pm - 1.00pm	The Levinia Crooks Emerging Leader Award Presentation
1.00pm - 2.00pm	Lunch

1.15pm - 2.00pm	Cepheid Sponsored Symposium Room: Grand Lodge Chairs: Andrew Lloyd, The Kirby Institute, UNSW Sydney, NSW
1.15pm - 1.35pm	Implementing Point of Care HCV Viral Load Fingerstick in a prison setting Marian Bloomfield, Justice Health, NSW
1.35pm - 1.55pm	Van (Liver)Life, taking Point of Care testing on the road Kristen McKee, Storr Liver Centre Westmead, NSW
2.00pm - 3.30pm	Proffered Paper Session 02 Room: Grand Lodge Chairs: Vanessa Towell, WHO Collaborating Centre for Viral Hepatitis & Rosemary Gilliver, Kirkeaton Road Centre
2.00pm - 2.15pm	Interventions to Enhance Testing and Treatment Uptake for Hepatitis C Infection: A Systematic Review and Meta-Analysis Evan Cunningham, The Kirby Institute, UNSW Sydney, NSW
2.15pm - 2.30pm	Hepatitis C Testing and Gaining Informed Consent: Taking Stock and Innovating for the Future Emily Lenton, Australian Research in Sex, Health and Society, VIC
2.30pm - 2.45pm	Rapid point of care HCV testing allows high throughput HCV screening and rapid treatment uptake among PWID attending a medically supervised injecting room Michael Macisaac, St Vincent's Hospital Melbourne, VIC
2.45pm - 3.00pm	Point-of-care HCV RNA testing, linkage to nursing care, and peer-supported engagement and delivery to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study Jason Grebely, The Kirby Institute, UNSW Sydney, NSW
3.00pm - 3.05pm	Sentinel Surveillance of Hepatitis Cc Antibody Testing, Victoria, Australia, 2009 to 2019 Anna Wilkinson, Burnet Institute, VIC
3.05pm - 3.10pm	Exploring the Potential use of Notification Data to Increase Hepatitis C Treatment Uptake Shelley Walker, Burnet Institute, VIC
3.10pm - 3.15pm	Slipping Through the Cracks? The Efficacy of Opt-Out HCV Testing in a Primary Health Care Facility Serving Marginalised Populations Vincent Cornelisse, Kirkeaton Road Centre, NSW
3.15pm - 3.20pm	Prison Transition Program, a Community-Based Program; that Facilitates the Continuity of Care for Clients in Different Phases of HCV Treatment Among People Transitioning in or Out of Correctional Centre in South East Dorrit Grimstrup, QulHN, QLD
3.20pm - 3.25pm	Evaluation of the 'Peers Assisting Treatment of Hepatitis C' (PATH) Model in a Primary Care Setting in Melbourne, Australia Imogen Elsum, Burnet Institute, VIC and Carolyn Weidner, Harm Reduction Victoria, Melbourne, VIC
3.25pm - 3.30pm	Jurisdictional Disparities in Progress Towards Improving the Cascade of Care for Chronic Hepatitis B in Australia Karen McCulloch, WHO Collaborating Centre For Viral Hepatitis, Doherty Institute, VIC
3.30pm - 4.00pm	Afternoon Tea
4.00pm- 5.30pm	Invited Speaker Session 04 Room: Grand Lodge Chairs: Jack Wallace, Burnet Institute & John Didlick, Hepatitis Australia
4.00pm - 4.20pm	Nursing and viral hepatitis care Sinead Sheils, Royal Prince Alfred Hospital Gastroenterology & Liver, NSW
4.20pm - 4.40pm	Where are we on the Road to HBV Elimination and Cure? Peter Revill, The Doherty Institute, VIC
4.40pm - 5.00pm	Adapting to COVID-19 Phill Read, Kirkeaton Road Centre, NSW
5.00pm - 5.30pm	Questions & Discussion
5.35pm - 6.05pm	Networking Drinks

LIVE PROGRAM

DAY 3: TUESDAY 1 JUNE – SYDNEY

8.30am	Registration opens
9.10am - 10.45am	Invited Speaker Session 05 Room: Grand Lodge Chairs: Mark Stoove, Burnet Institute & Jake Rance, Centre for Social Research in Health, UNSW Sydney, NSW
9.00am - 9.10am	Tribute to Jude Byrne Annie Madden, Centre for Social Research in Health UNSW Sydney, NSW
9.10am - 9.30am	How much will it cost to eliminate viral hepatitis? Nick Scott, Burnet Institute, VIC
9.30am - 9.50am	Prisons Colette McGrath, Justice Health Forensic Mental Health Network, NSW
9.50am - 10.10am	Government and policy maker role in elimination Stuart Manoj-Margison, Australian Government Department of Health, ACT
10.10am - 10.40am	Questions & Discussion
10.40am - 10.45am	Hepatitis Australia Statement Carrie Fowlie, Hepatitis Australia, ACT
10.45am - 11.15am	Morning Tea
11.15am - 12.45pm	Plenary 03 Room: Grand Lodge Chairs: Amanda Wade, Barwon Health & Behzad Hajarizadeh, The Kirby Institute, UNSW Sydney
11.15am - 11.45am	Keynote Presentation 05: Success and challenges in addressing viral hepatitis in the Asia-Pacific Saeed Sadiq Hamid, Professor, Department of Medicine and Director of the Clinical Trials Unit, The Aga Khan University, Karachi, Pakistan
11.45am - 12.15pm	Keynote Presentation 06: Progress and future challenges for enhancing viral hepatitis care in Aboriginal and Torres Strait Islander people Dawn Casey, National Aboriginal Community Controlled Health Organisation, ACT
12.15pm - 12.30pm	Development, Delivery and Evaluation of a Culturally Safe Hepatitis B Management Education Course for the Aboriginal Workforce to Increase Access and Reduce Health Inequity Amanda Dhagapan, Emily Vintour-Cesar, Phillip Wilson, Kelly Hosking, Teresa De Santis & Terese Ngurruwuthun, Menzies School of Health Research, NT
12.30pm - 12.45pm	Hepatitis C Imaginaries: Findings from a New Study on Stigma, Discrimination and Post-Cure Lives Kate Seear, La Trobe University, VIC
12.45pm - 1.45pm	Lunch
1.45pm - 2.45pm	Proffered Paper Session 03 Room: Grand Lodge Chairs: Colette McGrath, Justice Health Forensic Mental Health Network & Evan Cunningham, The Kirby Institute, UNSW Sydney

1.45pm - 2.00pm	Identifying Enablers that Facilitate Hepatitis B Clinical Management in Primary Care Settings Jack Wallace, Burnet Institute, VIC
2.00pm - 2.15pm	Quantifying Nurses Contribution to HCV Care Milestones: Findings from an Integrated Primary Healthcare Setting for Marginalised People Rosie Gilliver, Kirketon Road Centre, NSW
2.15pm - 2.30pm	“We’ve had a Circuit Breaker for an Old Dogma of More Than 20 Years”: Changes to Opioid Agonist Treatment Services During COVID-19, the CHOICE Study Anna Conway, The Kirby Institute, UNSW Sydney, NSW
2.30pm - 2.45pm	A Hidden Population: Supporting Healthy Ageing for People Who Inject Drugs Harini Walthati, AIVL, ACT
2.45pm - 2.50pm	A Qualitative Exploration of Enablers to Hepatitis B Clinical Management Among Ethnic Chinese in Australia Yinzong Xiao, Burnet Institute, VIC
2.50pm - 2.55pm	Find the Hero Inside You: World Hepatitis Day Digital Campaign Samantha White, Hepatitis Queensland, QLD
2.55pm - 3.00pm	A Costing Analysis of a State-Wide, Nurse-Led Hepatitis C Treatment Model in Prison Anna Palmer, Burnet Institute, VIC
3.00pm - 3.05pm	A Culturally Appropriate Evaluation of the “Hep B Story” App in a Remote Australian Community in Arnhem Land Paula Binks & George Gurruwiwi, Menzies School Of Health Research, NT
3.05pm - 3.10pm	Violence and Hepatitis C Transmission in Prison – A Modified Social Ecological Model Hossain Sazzad, The Kirby Institute, UNSW Sydney, NSW
3.10pm - 3.15pm	Reinfection in the Reach-C Cohort: Occurrence and Effectiveness of Retreatment for Hepatitis C Virus Reinfection Following Direct Acting Antiviral Therapy Joanne Carson, UNSW, NSW
3.15pm - 3.45pm	Afternoon Tea and Poster Viewing
3.45pm - 4.45pm	Closing Plenary Room: Grand Lodge Chairs: Annie Madden, Centre for Social Research in Health, UNSW & Carla Treloar, Centre for Social Research in Health, UNSW
3.45pm - 4.30pm	Next steps in viral hepatitis responses: Perspectives from people with lived experience in honour of Jude Byrne <i>Facilitators:</i> Annie Madden, Centre for Social Research in Health, UNSW, NSW & Carla Treloar, Centre for Social Research in Health, UNSW, NSW <i>Panellists:</i> Thomas Tu, University of Sydney and Westmead Institute for Medical Research, NSW; Nafisa Yussf, WHO Collaborating Centre for Viral Hepatitis, VIC; Lien Tran, WHO Collaborating Centre for Viral Hepatitis, VIC; Jack Wallace, Burnet Institute, VIC; Chris Gough, CAHMA and the Connection, ACT
4.30pm - 4.40pm	Committee Closing Remarks Jason Grebely, The Kirby Institute, UNSW Sydney, NSW
4.40pm - 4.45pm	ASHM Closing Remarks Alexis Apostolellis, Chief Executive Officer, The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, NSW

ON DEMAND PROGRAM

INVITED SPEAKER SESSIONS

View the On Demand content via the virtual event portal.
Design your own program and watch at your leisure.

Nursing and viral hepatitis care
Viral hepatitis care for Aboriginal and Torres Strait Islander peoples in the Northern Territory <i>Matthew Maddison, Royal Darwin Hospital, NT</i>
'Everything is Free' by the Midland Community Hep C Service <i>Nancy Carey, Waikato District Health Board, NZ & Jo DeLisle, HealthShare Ltd., NZ</i>
Homelessness, Hepatitis C and health inequality <i>Karyn Gellie, Bolton Clarke, VIC</i>
Taking stock of HCV elimination efforts: Where are we now and what are the challenges for the future?
Progress towards HCV elimination in Australia: should we be worried? <i>Greg Dore, The Kirby Institute UNSW Sydney, NSW</i>
Adapting the workforce as we strive for elimination <i>Jacqui Richmond, Burnet Institute, VIC</i>
Where are we now and what are the challenges for the future - community awareness and mobilisation <i>Carrie Fowlie, Hepatitis Australia, ACT</i>
Elimination agenda or epidemic management, our choice. <i>Michael West, Department of Health and Human Services, VIC</i>
Community and peer led models of testing and care
Care in your community - the power of peers <i>Leanne Myers, Peer Based Harm Reduction WA</i>
Providing In reach POCT to Methadone dosing centres <i>Tegan Nuckey, QuIHN, QLD</i>
Prisons
Individual-based models to simulate treatment scenarios for mitigating HCV in the prison setting <i>Neil Arvin Bretana, Denmark</i>
Integrating all modalities of hepatitis C testing into a comprehensive model for the NSW correctional system <i>Marian Bloomfield, Justice Health and Forensic Mental Health, NSW</i>
Interview with Anne Craigie <i>Sam White, Hepatitis Queensland, QLD & Anne Craigie, St Vincent's Hospital, VIC</i>
Innovative Testing Interventions - Implementation Successes and Challenges
Implementation of dried blood spot (DBS) testing in practice - lessons learned from the NSW DBS Pilot <i>Phillip Cunningham, St Vincent's Hospital, NSW</i>

<p>Implementing point-of-care HCV RNA testing in community-based needle and syringe program services: Successes and challenge <i>Amanda Kvassay, QulHN, QLD</i></p>
<p>Point-of-care HCV RNA testing in reception prisons <i>Yumi Sheehan, The Kirby Institute, UNSW Sydney, NSW</i></p>
<p>Point-of-care antibody testing and reflex point-of-care HCV RNA testing in drug treatment, mental health and prisons: A nursing perspective <i>Lucy Ralton, Royal Adelaide Hospital, SA</i></p>
<p>Successes and challenges of point-of-care HCV RNA testing in the Melbourne Medical Supervised Injecting Centre <i>Michael Macisaac, St Vincent's Hospital Melbourne, VIC</i></p>
<p>Using data linkage to better understand progress towards viral elimination targets</p>
<p>Hepatitis C treatment progress and impacts in NSW: insights from data linkage <i>Maryam Alavi, The Kirby Institute, UNSW Sydney, NSW</i></p>
<p>Elimination of mother-to-child transmission of hepatitis B in Queensland: achievements and gaps <i>Stephen Lambert, The University of Queensland, QLD</i></p>
<p>Using linkage to assess the cascade of care for hepatitis B in NT <i>Kelly Hosking, Menzies School of Health Research, NT</i></p>
<p>Data linkage priorities to guide the next phase of hepatitis C elimination <i>Mark Stoové, Burnet Institute, VIC</i></p>
<p>Health promotion messaging and campaigns</p>
<p>Effective health promotion targeting diverse populations <i>Grace Hogan, Hepatitis Australia, ACT</i></p>
<p>Co-design in health promotion <i>Charles Henderson, NUAA, NSW</i></p>
<p>Connecting the dots across multiple platforms <i>Lana Richardson, Hepatitis Queensland, QLD</i></p>
<p>CORRIDORS OF CONTROL – Providing prisoner programs in Victoria <i>Neylan Aykut, LiverWELL Limited, VIC</i></p>
<p>Liver cancer prevention, surveillance, and screening</p>
<p>Overview of HCC diagnosis, prevention, screening in community, treatment <i>Jess Howell, Burnet Institute, VIC</i></p>
<p>Engagement and management of people in HCC care, timeliness of surveillance and referral <i>Megan Collins, Sir Charles Gairdner Hospital, WA</i></p>
<p>HCC in Aboriginal and Torres Strait Islander peoples <i>Alison Hempenstall, Torres And Cape Hospital And Health Service, QLD</i></p>
<p>Constructing the cascade: Addressing hepatitis B in The Pacific – Sponsored by ASHM International</p>
<p>Understanding the Challenge of HBV in the Pacific & Building Support for National Response <i>Polin Chan, WHO Western Pacific Regional Office</i></p>
<p>Triple Elimination of Mother to Child Transmission – The Keystone of the Cascade <i>Nicole Allard, WHO Collaborating Centre for Viral Hepatitis, VIC</i></p>
<p>Pilot to Population – Sustainable Scaling of HBV Services in Kiribati <i>Rosemary Tekoaau, Kiribati Ministry of Health</i></p>

<p>Harnessing Private Partnerships for HBV Care in PNG <i>Sue Huntley, Hepatitis B Free</i></p>
<p>Building A National Response for HBV in Solomon Islands <i>Jackson Rakei, Solomon Islands Ministry of Health</i></p>
<p>Closing the Cascade <i>Benjamin Cowie, The Peter Doherty Institute for Infection and Immunity</i></p>
<p>Innovative models of hepatitis C & hepatitis B care</p>
<p>Overcoming barriers in hepatitis B – Innovative models of care <i>Jess Howell, Burnet Institute, VIC</i></p>
<p>Assessing the Impact of the EC Nurse-Led Model of Care on Hepatitis C (HCV) Testing Coverage in a Network of High Caseload Primary Care Clinics <i>Chloe Layton, Burnet Institute, VIC</i></p>
<p>Effectiveness of a community outreach program to improve access to FibroScan® for clients with chronic Hepatitis B <i>Jo Durham, Queensland University, QLD</i></p>
<p>Regional Clinical Development Project (The Hep C Hunter) <i>Jacqueline Del Bravo, Hepatitis WA</i></p>
<p>Community Outreach Nurse Project – Why Everyone Still Needs a Nurse <i>Jeannette Tibbs, Hepatitis Queensland, QLD</i></p>
<p>Innovative interventions to enhance hepatitis C care</p>
<p>Medical Chart Reminders <i>Mamta Jain, UT South Western, United States</i></p>
<p>Provider Care Coordination <i>Matthew Hickman, University of Bristol, United Kingdom</i></p>
<p>Patient Navigation <i>Sean Falade-Nwulie, Johns Hopkins Medicine, United States</i></p>
<p>Engaging GP's in treating Hepatitis C in Western Victoria <i>Amanda Wade, Barwon Health, VIC</i></p>
<p>Progress and future challenges for enhancing viral hepatitis care in Aboriginal and Torres Strait Islander people</p>
<p>Eliminate Hepatitis C Project <i>Deisha Price, Aboriginal Health Council of Western Australia, WA</i></p>
<p>Strengthening workforce capacity to increase hepatitis c testing and treatment among urban Aboriginal and Torres Strait Islander People <i>Linda Selvey, The University of Queensland, QLD & Renée Brown, Institute for Urban Indigenous Health, QLD</i></p>
<p>Innovative interventions to enhance hepatitis B care</p>
<p>Consumer influence on LiverWELL App enhancements <i>Isabelle Purcell, LiverWELL, VIC</i></p>
<p>HepLOGIC – Hepatitis and liver cancer outcomes in general practice: an intervention collaboration <i>Nicole Allard, VIDRL, Doherty Institute, VIC</i></p>
<p>Models of hepatitis B care in remote Aboriginal communities in the Northern Territory <i>Kelly Hosking, Menzies School of Health Research, NT</i></p>

ON DEMAND PROGRAM

ORAL ABSTRACTS

View the On Demand content via the virtual event portal.
Design your own program and watch at your leisure.

Biomedical and Clinical Oral Abstracts

#085 Contribution of General Practitioners in Hepatitis C Treatment in Australia: Experience of an Unrestricted Model of Direct-Acting Antiviral Treatment Program
Behzad Hajari, The Kirby Institute, UNSW Sydney, NSW

#090 Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in patients with chronic hepatitis (HCV) infection and psychiatric disorders: real-world care management from 6 countries.
Mary Fenech, QuIHN, QLD

#053 Focus on HCV Elimination in Community Settings (Community Based OST Dispensing Pharmacies) Via a Mobile Clinic
Kristen McKee, Western Sydney LHD, NSW

#050 Functional Cure of Chronic Hepatitis B is Associated with Co-Occurrence of HBSAG/ Anti-HBS Immune Complex Peaks with Alt Flares, and Seroconversion to Potently Neutralising Anti-HBS
Hui Xu, VIDRL, The Doherty Institute, VIC

#091 Hepatitis C Virus (HCV) Elimination in People Who Inject Drugs (PWID): Sofosbuvir/Velpatasvir (SOF/VEL) as a Simple Tool to Implement a Test and Treat Approach in this Vulnerable Population
Joss O'loan, Kombi Clinic, QLD

#024 Community-Based Care for Viral Hepatitis - A Survey of General Practitioners' Perspectives in Brisbane, Australia
Belaynew Taye, The University of Queensland, QLD

#136 Hepatitis C Point of Care Testing - Implementation Learnings and Early Results from QuIHN NSP's
Amanda Kvassay, QuIHN, QLD

#012 DRIED BLOOD SPOT (DBS) TESTING PILOT - Client-centred testing and treatment (or reaching the high hanging fruit)
Nigel Carrington, Sydney Sexual Health Centre, NSW

#135 Hepatitis C Testing and Treatment in NSP Settings - A QuIHN Perspective
Amanda Kvassay, QuIHN, QLD

#126 Diagnostic Accuracy of Assays Using Finger-Stick Capillary and Dried Blood Spot Samples for Determination of Hepatitis C RNA Detection: A Systematic Review and Meta-Analysis
Beth Catlett, The Kirby Institute, UNSW Sydney, NSW

#076 Hepatitis in Prison Elimination Program Video: Highlighting Contribution of People in Custody to Elimination Efforts
Tracey Brown, Justice Health And Forensic Mental Health Network, NSW

Epidemiology & Public Health Oral Abstracts

#048 Hepatitis C Virus Reinfection Following Direct Acting Antiviral Treatment in the Prison Setting: The Stop-C Study
Joanne Carson, The Kirby Institute, UNSW Sydney, NSW

#105 Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression
Samira Hosseini-Hooshyar, The Kirby Institute, UNSW Sydney, NSW

#031 A Guide to Scale-Up of Testing and Treatment for Hepatitis C in the Prison Setting: The Stop-C Implementation Toolkit
Marianne Byrne, The Kirby Institute, UNSW Sydney, NSW

#082 Assessment of the Cost-Effectiveness of Australia's Risk-Sharing Agreement for Direct-Acting Antiviral Treatments for Hepatitis C
Nick Scott, Burnet Institute, VIC

#142 The cost-effectiveness of general population testing for hepatitis B in Australia
Yinzong Xiao, Burnet Institute, VIC

#072 Association Between Health Service Utilisation and Experiences of Stigma Among People at Risk of, or Living with, Hepatitis C in Melbourne, Australia
Filip Djordjevic, Burnet Institute, VIC

#102 Evaluation of the HCV Cascade of Care Among People with HIV/ Hepatitis C Co-Infection in New South Wales, Australia: A Data Linkage Study
Samira Hosseini-Hooshyar, The Kirby Institute, UNSW Sydney, NSW

#125 Managing Hepatitis B in the Western Desert: The Ngaanyatjarra Health Service Approach
David Scrimgeour, Ngaanyatjarra Health Service, SA

#112 Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalised People with Recent Drug Dependence in New South Wales, Australia: A Population-Based Linkage Study
Heather Valerio, The Kirby Institute, UNSW Sydney, NSW

#084 Efficacy of Harm Reduction and Community Mental Health Staff Testing and Treating Hepatitis C at a Regional Needle and Syringe Program: A Retrospective Cohort Study.
Amanda Wade, Barwon Health, VIC

#120 Changes in Hepatitis C Testing Among Individuals Attending Primary Care Services Specialising in PWID Services in Victoria, Australia Following COVID-19 Restrictions
Michael Traeger, Burnet Institute, VIC

#101 Hepatitis C Virus Antibody Testing Among Opioid Agonist Therapy Recipients, Victoria, Australia, 2012 to 2019
Joshua Dawe, Burnet Institute, VIC

#131 Hepatitis C Virus Reinfection Incidence Among Gay, Bisexual and Other Men who Have Sex with Men Living with HIV Before and After the Availability of Direct Acting Antivirals in Australia
Brendan Harney, Burnet Institute, VIC

Community & Social Science Oral Abstracts

#045 Supercharging the Digital Highway, One Video at a Time
Jessie Badger, Hepatitis Queensland, QLD

#088 Correctional Officers and Justice Health Staff Perspectives of Hepatitis C Treatment as Prevention Scale up Within the Prison Setting
Lise Lafferty, Centre for Social Research in Health, UNSW Sydney, NSW

#026 The Centre or the Periphery? Social Relationships and Hepatitis C Treatment in the Elimination Era
Adrian Farrugia, La Trobe University, VIC

#016 Knowledge and Beliefs about Hepatitis B Virus Infection and Associated Factors Among Chinese Migrants in Australia
Defeng Jin, Centre for Social Research in Health, UNSW Sydney, NSW

#100 Delivering Education to Aboriginal and Torres Strait Islander Health Workers and Health Practitioners in an Online Environment

Phoebe Schroder, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, NSW

#079 Barriers to Hepatitis C Testing and Treatment Experienced by Sub-Groups of People who Inject Drugs

Jack Gunn, Burnet Institute, VIC

#096 Hepatitis C Free Cairns: Using Incentives to Increase Access to Hepatitis C Testing and Treatment

Carla Gorton, Cairns Sexual Health Service

#035 Digital Innovations in Viral Hepatitis and Liver Health During COVID-19

Isabelle Purcell, LiverWELL Limited, VIC

#067 Peer Based Advice for People Newly Diagnosed with Hepatitis B

Jack Wallace, Burnet Institute, VIC

#109 Creating a National Hepatitis C Health Promotion Campaign for People Who Inject Drugs

Emily Adamson, Burnet Institute, VIC

#147 HepBCommunity.org: a global online forum dedicated to supporting people with hepatitis B

Thomas Tu, University Of Sydney And Westmead Institute For Medical Research, NSW

#040 Pandemic Preparedness: The Future of Workforce Development Programs on Viral Hepatitis and Liver Health

Pearl Prabal, LiverWELL Limited, VIC

#052 Success of a Non-Clinical Service Offering HIV and Hepatitis C Dried Blood Spot Testing in Community

Ana Romero, Sydney Local Health District, NSW

#011 Educating from Inside Out - Learnings from Peer Educators in Townsville Correctional Centre

Suzanne Wales, QuIHN, QLD

#095 When Making a Video is More than Point and Shoot

Marriane Black, Ethnic Communities Council of Queensland, QLD

#110 Assessing the Impact of a Hepatitis C Testing Initiatives Program - A Method to Expand Our Collaborative Peer Based Model of Care

Leanne Myers, Peer Based Harm Reduction WA

#033 Health Literacy and Hepatitis C Education in Australian Prisons: A National Needs Assessment

Yumi Sheehan, The Kirby Institute, UNSW Sydney, NSW

#132 Challenges of Getting People Tested and Treated - Perspectives from a Peer Harm Reduction Worker

Esha Leyden, QuIHN, QLD

#065 Identifying Enablers to Integrating Hepatitis C into Primary Care Nurses' Scope of Practice

Jacqui Richmond, Burnet Institute, VIC

ON DEMAND PROGRAM

POSTER LISTING

View the On Demand content via the virtual event portal.
Design your own program and watch at your leisure.

Biomedical & Clinical Poster Abstract Presentations

#092 Value of Sofosbuvir/Velpatasvir (SOF/VEL) as pangenotypic panfibrotic hepatitis c virus (HCV) treatment in implementing a test and treat strategy in prisons: real-world care management from 6 countries.

Joss O'Loan, Kombi Clinic

#068 PROMPt – Point of care testing for Hepatitis C in the priority settings of mental health, prisons ad drug & alcohol facilities

Lucy Ralton, Royal Adelaide Hospital, SA

#099 Time for universal hepatitis B screening for Australian adults

Lien Tran, WHO Collaborating Centre For Viral Hepatitis

#027 Testing on the periphery: partnerships for optimising hiv and hepatitis c results delivery for priority populations

Aurelie Kenigsberg, NSW Sexual Health Infolink

#066 Continuing workforce education delivery during a pandemic: conversion to online delivery of the HBVs100 prescriber course

Rachel Byrne, ASHM

Community & Social Science Poster Abstract Presentations

#071 The Juice: Developing a health promotion resource for people who inject performance and image enhancing drugs

Grace Hogan, Hepatitis Australia

#078 Postcards from prison: creating partnerships and innovative health promotion during COVID

Ruth Bearpark, Hepatitis NSW

#108 Are you living with Hepatitis B? Find out. Get tested.

Ella Negrine, Multicultural HIV and Hepatitis Service, NSW

#073 Ensuring community voices are heard during a pandemic

Grace Crowley, Hepatitis NSW

#094 When you don't speak their lingo? How bi-lingual community health workers can increase the knowledge retention for viral hepatitis

Marriane Black, Ethnic Communities Council of Queensland, QLD

#049 B tested, B vaccinated, B stronger

Lana Richardson, Hepatitis Queensland

#041 Looking to community corrections for 'hardly reached' HCV patients - a new approach to achieve HCV elimination in Australia

Winnie Nguyen, Hepatitis Queensland

#039 Community participation in the time of COVID

Neylan Aykut, LiverWELL Limited

#056 Digital pathways to HEP C elimination: the Hepconnect program

Sandy Davidson, Hepatitis NSW

Epidemiology & Public Health Poster Abstract Presentations

#039 Community participation in the time of COVID

Neylan Aykut, LiverWELL Limited

#038 Innovative partnership with rotary - "end hepatitis now"

Kay Dufty, LiverWELL Limited

#037 Sharing holistic liver health resources for Aboriginal and Torres Strait Islander communities

Kay Dufty, LiverWELL Limited

#145 Eliminating hepatitis C in Australia - a successful nurse-led statewide program for hepatitis C treatment in Victorian prisons

Michael Maclsaac, St Vincent's Hospital Melbourne, VIC

#017 "I've no money, I'm about to be evicted": characteristics of clients and utility of receiving copayment support for direct acting antiviral therapy

Rosie Gilliver, Kirketon Road Centre, NSW

#114 A successful hepatitis C outreach service in a medically supervised injecting room: increased uptake of screening and high rates of treatment initiation

Michael Maclsaac, St Vincent's Hospital Melbourne, VIC

#028 Nurse led model of care supporting general practitioners in the management of Hepatitis B within Western Sydney

Kindness Bondezi, Westmead Hospital, NSW

#021 Autochthonous and travel acquired Hepatitis E Virus in Australia

Kathy Jackson, VIDRL, VIC

#064 A modelling analysis of financial incentives for hepatitis c testing and treatment uptake delivered through a community-based testing campaign

Anna Palmer, Burnet Institute, VIC

#081 Clearing the path: a partnership to deliver a communications campaign to increase hepatitis c treatment access for people who inject drugs

Maria McMahon, Hepatitis NSW

#019 Post- Vaccination serological outcomes for infants born to women infected with HEPATITIS B

Lai Ping Elsa Chu, Royal North Shore Hospital, NSW

#104 Hepatitis C incidence in primary care clinics, Victoria, Australia, 2009 to 2019.

Anna Wilkinson, Burnet Institute, VIC

#115 Awareness of HCV infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: the ethos engage study

Heather Valerio, The Kirby Institute, UNSW, NSW

#124 No evidence of association of methamphetamine injecting on current hepatitis c infection: the ethos engage study
Heather Valerio, The Kirby Institute, UNSW, NSW

#119 Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system
Daisy Gibbs, National Drug And Alcohol Research Centre

#025 Healthcare Implications of The Epidemiology And Health Literacy For Viral Hepatitis In Culturally and Linguistically Diverse Communities In Australia
Belaynew Taye, The University Of Queensland

#129 Hepatitis B and Hepatitis C Policies In The Western Pacific Region: Pregnancy And Paediatrics Gaps
Farihah Malik, University College London (UCL)

#140 Impacts of an educational program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot and feasibility study
Yinzong Xiao, Burnet Institute

#139 A systematic review of risk factors for chronic Hepatitis B infection in Chinese adults
Elizabeth Hamilton, University Of Oxford

#075 Reaching corners of the yard services cannot: a prison based hepatitis and harm reduction peer education pilot
Tom Wright, Justice Health and Forensic Mental Health Network


#122 Opioid overdose and naloxone access among people who recently used opioids or received opioid agonist treatment in Australia: the ETHOS Engage Study
Anna Conway, The Kirby Institute, UNSW, NSW

#057 Exploring Hepatitis C Virus Testing and Treatment Engagement In Melbourne, Australia: Baseline Results from the ec Experience Prospective Cohort Study
Daniel O'Keefe, Burnet Institute

#087 A randomised controlled trial of active case management to link hepatitis c notifications to hepatitis c treatment in Tasmania - a study protocol
Tafireyi Marukutira, Burnet Institute

#137 Finding Thousands: Test, Cure, Live National Campaign
Wendy Anderson, Hepatitis Australia

NOTES



vh2022

SAVE THE 29-31 MAY DATE

**13th Australasian Viral
Hepatitis Conference
29-31 May 2022
Sofitel Brisbane Central**

[HEPATITIS.ORG.AU](https://www.hepatitis.org.au)

